Industry wants broader health technology assessments, says new report
This article was originally published in Scrip
Executive Summary
Health technology assessment (HTA) should be broader, says a new report commissioned by the R&D-based pharmaceutical industry. Assessments that take on the views of a wider stakeholder groups or incorporate more technologies, for example, would provide a wider evidence base to support the use of drugs under scrutiny, said Edith Frénoy, director of market access at the European Federation of Pharmaceutical Industry Associations (EFPIA).
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.